1. Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-7.

https://doi.org/10.1016/S0278-2391(03)00720-1

PMid:12966493

2. Marx R, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg. 2005;63:1567-75.

https://doi.org/10.1016/j.joms.2005.07.010

PMid:16243172 

3. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99-102.

https://doi.org/10.1056/NEJM200507073530120

PMid:16000365 

4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication- related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.

https://doi.org/10.1016/j.joms.2014.04.031

PMid:25234529 

5. Murphy J, Mannion CJ. Medication-related osteonecrosis of the jaws and quality of life: review and structured analysis. Br J Oral Maxillofac Surg. 2020;58:619-24.

https://doi.org/10.1016/j.bjoms.2020.03.010

PMid:32247520 

6. Tenore G, Mohsen A, Rossi AF, Palaia G, Rocchetti F, Cassoni A, et al. Does Medication-Related Osteonecrosis of the Jaw Influence the Quality of Life of Cancer Patients?. Biomedicines. 2020;24:8-95.

https://doi.org/10.3390/biomedicines8040095

PMid:32344782 PMCid:PMC7235831

7. Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:529-35.

PMid:10453668

8. Lopez-Jornet P, Sanchez Perez A, Amaral Mendes R, Tobias A. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment?. A systematic review. J Craniomaxillofac Surg. 2016;44:1067-72.Surg. 2016;44:1067-72.

PMid:27318752

9. Del Fabbro M, Gallesio G, Mozzati M. Autologous platelet concentrates for bisphosphonate-related osteonecrosis of the jaw treatment and prevention. A systematic review of the literature. Eur J Cancer. 2015;51:62-74.

https://doi.org/10.1016/j.ejca.2014.10.015

PMid:25466505 

10. Longo F, Guida A, Aversa C, Pavone E, Di Costanzo G, Ramaglia L, et al. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent. 2014;2014:298945.

PMid:25013411

11. Bocanegra-Pérez S, Vicente-Barrero M, Knezevic M, Castellano-Navarro JM,Rodríguez-Bocanegra E, Rodríguez-Millares J, et al. Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Int J Oral Maxillofac Surg. 2012;41:1410-5.

https://doi.org/10.1016/j.ijom.2012.04.020

PMid:22647765 

12. Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M. Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol. 2012;48:469-74.

https://doi.org/10.1016/j.oraloncology.2011.12.004

PMid:22265335 

13. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol. 2012;48:817-21

https://doi.org/10.1016/j.oraloncology.2012.03.009

PMid:22483860 

14. Barba-Recreo P, Del Castillo Pardo de Vera JL, Georgiev-Hristov T, Ruiz Bravo-Burguillos E, Abarrategi A, Burgueño M, et al. Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model. J Craniomaxillofac Surg. 2015;43:1161-8.

https://doi.org/10.1016/j.jcms.2015.04.026

PMid:26027865 

15. Fortunato L. Bennardo F. Buffone C. Giudice A. Is the application of platelet concentrates effective in the prevention and treatment of medication-related osteonecrosis of the jaw? A systematic review. J Craniomaxillofac Surg. 2020;48:268-85.

https://doi.org/10.1016/j.jcms.2020.01.014

PMid:32063481 

16. Curi M, Cardoso C, Koga D, Zardetto C. Bisphosphonate-related osteonecrosis of the jaws-an initial case series report of treatment combining marginal bone resection and autologous platelet-rich plasma. J Oral Maxillofac Sur. 2011;69:2465-72.

https://doi.org/10.1016/j.joms.2011.02.078

PMid:21763050 

17. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23.

https://doi.org/10.1002/jbmr.2405

PMid:25414052 

18. Nisi M, La Ferla F, Karapetsa D, Gennai S, Miccoli M, Baggiani A, et al. Risk factors influencing BRONJ staging in patients receiving intravenous bisphosphonates: a multivariate analysis. J Oral Maxillofac Surg. 2015;44:586-91.

https://doi.org/10.1016/j.ijom.2015.01.014

PMid:25701305 

19. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case- control study. J Oral Maxillofac Surg. 2008;66:625-31.

https://doi.org/10.1016/j.joms.2007.11.032

PMid:18355585 PMCid:PMC2435366

20. Kim HY, Lee SJ, Kim SM, Myoung H, Hwang SJ, Choi JY, et al. Extensive Surgical Procedures Result in Better Treatment Outcomes for Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Osteoporosis. J Oral Maxillofac Surg. 2017;75:1404-13.

https://doi.org/10.1016/j.joms.2016.12.014

PMid:28039736 

21. Kyrgidis A, Vahtsevanos K, Koloutsos G, Andreadis C, Boukovinas I, Teleioudis Z, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:4634-8.

https://doi.org/10.1200/JCO.2008.16.2768

PMid:18574158 

22. Tsao C, Darby I, Ebeling PR, Walsh K, O'Brien-Simpson N, Reynolds E, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013;71:1360-6.

https://doi.org/10.1016/j.joms.2013.02.016

PMid:23582590 

23. Barba-Recreo P, Del Castillo Pardo de Vera J, García-Arranz M, Yébenes L, Burgueño M. Zoledronic acid - Related osteonecrosis of the jaws. Experimental model with dental extractions in rats. J Craniomaxillofac Surg. 2014;42:744-50.

https://doi.org/10.1016/j.jcms.2013.11.005

PMid:24342733 

24. Sim Ie W, Sanders KM, Borromeo GL, Seymour JF, Ebeling PR. Declining incidence of medication-related osteonecrosis of the jaw in patients with cancer. J Clin Endocrinol Metab. 2015;100:3887-93.

https://doi.org/10.1210/jc.2015-1794

PMid:26241323 

25. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082-92.

https://doi.org/10.1016/j.ejca.2012.08.002

PMid:22975218 

26. Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME. Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis. Cancer Treat Rev. 2013;39:97-104.

https://doi.org/10.1016/j.ctrv.2012.07.002

PMid:22898302 PMCid:PMC3691016

27. Limones A, Sáez-Alcaide LM, Díaz-Parreño SA, Helm A, Bornstein MM, Molinero-Mourelle P. Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal. 2020;25:e326-36.

https://doi.org/10.4317/medoral.23324

PMid:32271321 PMCid:PMC7211372

28. Pilanci K, Alco G, Ordu C, Sarsenov D, Celebi F, Erdogan Z, et al. Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?. Medicine. 2015;94:e671.

https://doi.org/10.1097/MD.0000000000000671

PMid:25950681 PMCid:PMC4602532